Dr Linn Baal » Analyser

KöpTopoTarget

Topotarget – Belinostat Trials Shape the Future

Dr Linn Baal 2011-12-21 16:53 Communityanalys

It’s really pretty simple: providing that the results of the PTCL and CUP trials meet their respective endpoint, the outlook for the company by the end of 2012 will be prosperous. The forecast, based on the results of trials of efficacy and safety for the PTCL trial and model data for the CUP trial, is that there is a positive likelihood that this will happen. This makes Topotarget a promising investment opportunity for 2012, however, nothing should be taken for granted.

KöpTopoTarget

TopoTarget – High Time to Double

Dr Linn Baal 2011-01-15 15:21 Communityanalys

Lets face it, most indicators tell that belinostat will be on the market as soon as 2012. Given that the drug targets a multi-billion dollar market in combination with improved investor relations acting as catalyst, it is high time for a positive attitude towards belinostat, the company and the growth in market value. Recent calculations on company value supported by major interest in the field from a number of larger pharmaceutical companies clearly demonstrate a tremendous upside. A doubling in market value within the nearest time is likely.

SäljEpicept

EpiCept - riskerna överväger

Dr Linn Baal 2010-08-22 20:14 Communityanalys

Det finns en tydlig potential i EpiCepts pipeline men den skrala ekonomin och företagets dåliga track-record gör att den sannolikt inte kommer realiseras.

KöpTopoTarget

TopoTarget: bra risk-reward

Dr Linn Baal 2010-07-09 16:52 Communityanalys

TopoTargets aktie har misshandlats kraftigt den senaste tiden i likhet med många sektorkollegor. En ytlig analys av företaget visar dock på en stark fundamental grund och ett betydande mervärde i form av potential med ett gynnsamt risk-reward förhållande.